TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stress (short-term)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental health (long-term)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social behavior (long-term)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Kilocalories consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Specificity of detection of any cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of detection of any cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual's perception of their position in life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental impairments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of severe or worse non-hematological immune-related adverse event (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Exposure bone area (EBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Face, Legs, Movement, Crying, Avocative Behavioral Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin sensitization reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Skin irritation reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with normal mucosa, benign lesions, malignant tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Maltreatment Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Nutrition and Physical Activity Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical success rate of PEF treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PEF treatment related AE/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in optic disc and macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comfort while pumping
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of IgG antibodies to HPV-16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IgG antibodies to HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IgG antibodies to HEV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants recruited in recruitment period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who complete all data collection procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who complete study (retention)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who complete the intervention (adherence)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients without sustained atrial arrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic value of long non coding RNA UCA-1 and WRAP53
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mindful Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change from Baseline in Total Cholesterol at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change from Baseline in Fasting blood glucose at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of adverse effects of COVID-19 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity and persistence after COVID-19 vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (%Ae)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival recession depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Fat-free mass at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Body fat percentage at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Maximal isometric handgrip strength at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from 30-second chair stand test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Timed up-and-go test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physiological/clinical outcomes
Primary endpoint: Safety of DC injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: OSDI score difference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of single dose Z-338 before meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC up to 8 hours after administration of single dose Z-338 before meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination rate of three symptoms (Postprandial fullness, Upper abdominal bloating and Early satiation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall responder rate by the Overall Treatment Evaluation (OTE) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: one-year single-procedure clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of grade III-IV acute graft-versus-host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in functional upper extremity performance score as assessed by the WMFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate to GLX ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with interventions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in L*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in modified Melasma Area Severity Index (mMASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain-Anesthetic effect of AFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance (Cdyn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with at least 50% reduction of seizures per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: number of adverse events (according to CTCAE classification)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of remyelinated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in relative power of slow frequencies (alpha and theta rhythms) on the EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postoperative overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Center of Pressure Path Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Deviation of Center of Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Determinism of Postural Sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entropy (Sample Entropy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Volume of Infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiosensitivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Pimonidazole Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of radiographs leading to treatment consequences
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Driveline infection
Endpoint domain: Adverse events/effects
Primary endpoint: Time to complete resolution of angioedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission (complete or partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Hazardous Alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Gut Microbial alpha diversity measured by the Shannon index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients reaching PrEP adherence by Tenofovir Urine Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diuresis volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient willingness to participate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants in Remission After Switching to Vedolizumab SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported performance score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported comfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurocognitive test battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correct answers to management of paediatric febrile episode
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in resting systolic blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in resting diastolic blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in resting mean arterial blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence rates of post-COVID patients requiring multidisciplinary care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Impaired functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Microvascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal Numeric Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pacemaker-induced heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of low pressure versus standard pressure pneumoperitoneum
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of low pressure versus standard pressure pneumoperitoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in discrimination thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in healthcare appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nutritional Status Control (CONUT score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exophoria with cover test at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exophoria with cover test at 4 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety composite - Incidence of Treatment Emergent Adverse Clinical Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in endometriosis related dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometriosis related dyschezia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometriosis related dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometriosis related dysuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometriosis related pelvic chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of odds ratios for non-use of cessation services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of odds ratios for continuation or relapse of tobacco use
Endpoint domain: Adverse events/effects
Primary endpoint: dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survey response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurological Severity at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of reported AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative cardiac injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of SOP deviations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy against COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Reactions (AR)
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation of Galectin 3 levels with disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Primary Sjögren's Syndrome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of participants who develop brain aging-related conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Isometric Ankle Dorsiflexion Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric Ankle Plantar Flexion Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Mental Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in medication administration self-efficacy scale mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in clinical comfort and worry tool mean score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean of quantitative performance score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inspiratory reserve volume (IRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of the potential of hydrogen (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the partial arterial pressure of carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the partial arterial pressure of oxygen (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intact lower uterine segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Respiratory Rate (RR) / Breathing Rate (BR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Saturation (O2 Sat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in phase angle difference (PAD) between DLMO and waketime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Children's Depression Rating Scale (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recession defect coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage change in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in ALS Functional Rating Scale, Revised (ALS FRSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline SVC percent predicted at clinic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Dyspnea in Amyotrophic Lateral Sclerosis 15 (DALS-15)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of aneurysm wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Consistency of MTX concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Related Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Satisfaction with the Curriculum at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Participant's Rate of Completion of Weekly Blood Pressure Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Participant's Rate of Completion of Weekly Steps Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to heart transplant, recovery or 180 days of support in the absence of severe stroke
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from symptomatic stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change of total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of subjects with IGA grades decreased by ≥2 grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence changes of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: fluid cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gain in ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in facial swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Cerebritis, Meningitis, Bacterial Ventriculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Symptomatic Rebleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in baseline intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patient commitment to study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative number of new Gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of refugees dropping out of the introduction program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of refugees being unemployed after the end of the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wee Functional Independence Measure (Wee-FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With HR+ HER2- Advanced Breast Cancer Treatment Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum IL-25 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vaso-occlusive crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Proprietary Midface Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of respiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of respiratory muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes